ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag big pharma microbiology disease medicine

Make Mine Rare
Megan Scudellari | Aug 1, 2011 | 7 min read
With mounting interest from biotechs, Big Pharma, and the federal government, research on rare diseases is burgeoning.
Researchers in George Church&rsquo;s lab modified wild type ADK proteins (left) in <em >E.coli</em>, furnishing them with an nonstandard amino acid (nsAA) meant to biocontain the resulting bacterial strain.
A Pioneer of The Multiplex Frontier
Rashmi Shivni, Drug Discovery News | May 20, 2023 | 10 min read
George Church is at it again, this time using multiplex gene editing to create virus-proof cells, improve organ transplant success, and protect elephants.
Gut Microbes for Life
Ed Yong | Jul 4, 2013 | 3 min read
Most strains of gut microbes stay with us for decades, which may prove useful for tracking our health.
Bioterrorism Research: New Money, New Anxieties
John Dudley Miller | Apr 6, 2003 | 8 min read
Ned Shaw US scientists have reason to feel both heady and scared. The federal government recently released unprecedented billions of dollars to fund bioterrorism research. Yet, the merits of this sudden shift in focus are being debated, and some worry that the money will be squandered or wasted. "I have been really very upset by the focus on bioterrorism," says Stanley Falkow, professor of microbiology and immunology and of medicine at Stanford University. "Everybody's talking about it, but th
The Little Cell That Could
Megan Scudellari | Jul 1, 2012 | 7 min read
Critics point out that cell therapy has yet to top existing treatments. Biotech companies are setting out to change that—and prove that the technology can revolutionize medicine.
Overcoming Resistance
The Scientist | Apr 1, 2014 | 10+ min read
In the face of bacterial threats that can evade modern medicines, researchers are trying every trick in the book to develop new, effective antibiotics.
Alzheimer Research Joins the Mainstream
Christine Bahls | Jan 20, 2002 | 5 min read
In 1977, Alzheimer Disease researcher Peter Davies spoke with some neurologists about his work, which he began a year earlier. "One [neurologist] said, 'This is lovely..., but why don't you work on something that is more common?'" he remembers. Davies says the comment epitomized scientists' then-dismissive attitude about Alzheimer Disease (AD). When Alois Alzheimer first identified this memory-destroying disorder in 1907, his patient was a 50-year-old woman; a very early age, as researchers now
How Bacteria Interfere with Insect Reproduction
Ruth Williams | Feb 28, 2017 | 3 min read
Scientists identify the genes responsible for bacteria-controlled sterility in arthropods.
Updated July 9
Track COVID-19 Vaccines Advancing Through Clinical Trials
The Scientist | Apr 7, 2020 | 10+ min read
Find the latest updates in this one-stop resource, including efficacy data and side effects of approved shots, as well as progress on new candidates entering human studies.
Mapping the Terrain
Thana Poopat and Nantiya Tangwisutijit | Jan 12, 2010 | 10+ min read
color = "#B693B5"; Mapping the Terrain Thailand’s first National Biotechnology Policy Framework served as a roadmap for significant progress, but it had a rocky start. A look back at the Framework provides signposts to guide the way forward. By Thana Poopat and Nantiya Tangwisutijit During the past 3 decades, Thailand has increasingly prioritized biotechnology investment. From medicine to food to plastics to energy, Thailand has emerg

Run a Search

ADVERTISEMENT